Table 2.

Difference-in-differences analysis of mean C/D ratio of tacrolimus^a

Group	Week 2 C/Db (95% CI)	Week 6 C/Db (95% CI)	Difference: Week 6 − Week 2b (95% CI)	P
Maraviroc
unadjusted	3.87 (3.02–4.72)	4.59 (3.51–5.67)	0.72 (0.03–1.40)	0.04
adjustedc	2.21 (0.94–3.50)	2.99 (1.51–4.49)	0.78 (0.06–1.49)	0.03
Control
unadjusted	3.65 (2.87–4.43)	4.87 (3.89–5.86)	1.21 (0.58–1.84)	<0.001
adjustedc	2.26 (1.10–3.42)	3.39 (2.03–4.75)	1.13 (0.46–1.78)	0.01
Difference-in-differences
unadjusted			−0.49 (−1.39 to 0.40)	0.28
adjusted			−0.35 (−1.19 to 0.64)	0.46

^aIn the first step of the difference-in-differences calculation, intragroup changes in C/D ratio are estimated: the values in Week 2 are subtracted from those in Week 6. In the second step, the change from baseline is compared in each group: the Week 6 − Week 2 difference in the control group is subtracted from the Week 6 − Week 2 difference in the maraviroc group. The results presented here are those obtained before and after adjusting for confounding variables.

^bUnits are expressed as (ng/mL)/(mg/day).

^cAdjusted for weight, GVHD, antifungal exposure and corticosteroid exposure.